The TRACTION trial has found that tranexamic acid reduced the need for blood transfusions in patients undergoing major noncardiac surgery, without increasing the risk of dangerous blood clots.
What the Trial Found
A large clinical trial published in the New England Journal of Medicine has found that tranexamic acid — a drug that helps blood clot more effectively — reduced the need for red-cell transfusions during hospital stays for patients having major noncardiac surgery. The results come from the TRACTION trial, a cluster-randomised study, meaning hospitals rather than individual patients were randomly assigned to treatment groups.
The drug was also found to be non-inferior to placebo for venous thromboembolism — blood clots in the veins — within 90 days of surgery. That’s the finding that will reassure many clinicians. Tranexamic acid has historically raised questions about clotting risk, so evidence that it doesn’t increase that danger compared with placebo is medically meaningful.
Why Transfusions Matter
Blood transfusions aren’t without risk. They carry the potential for immune reactions, infection, and other complications, and they place significant demand on blood supply stocks. Reducing transfusion rates during major surgery is a longstanding goal in perioperative medicine — the branch of medicine concerned with patient care before, during, and after operations.
Noncardiac surgery covers a mix of procedures: bowel resections, hip replacements, major vascular operations. These are exactly the kinds of surgeries carried out every day across NHS trusts in Kent and across England.
Understanding the Study Design
The cluster-randomised design is worth understanding. Rather than randomising each patient individually, the trial assigned entire hospital clusters to either tranexamic acid or placebo. This approach can reflect real-world clinical practice more accurately, but it also introduces statistical complexity. The non-inferiority finding on blood clots means the researchers set out to show the drug was no worse than placebo by a defined margin — not necessarily that it was better.
According to the NEJM, which posted the findings, the full TRACTION trial results are now available. No specific patient numbers or effect sizes were included in the published summary referenced here, so the precise scale of the transfusion reduction remains to be assessed from the full paper.
What It Could Mean in Practice
If the findings hold up to scrutiny and are adopted into clinical guidelines, tranexamic acid could become more widely used in surgical settings across the NHS. That said, guideline changes follow evidence reviews — they don’t happen overnight.
—
Source: @NEJM
Key Takeaways
- The TRACTION trial found tranexamic acid reduced red-cell transfusion rates in patients undergoing major noncardiac surgery
- The drug was non-inferior to placebo for venous thromboembolism risk within 90 days, addressing a key safety concern
- The trial used a cluster-randomised design, with results published in the New England Journal of Medicine
What This Means for Kent Residents
Patients in Kent facing major surgery — whether at Maidstone and Tunbridge Wells NHS Trust, East Kent Hospitals, or Dartford and Gravesham NHS Trust — may eventually benefit if these findings influence NHS prescribing practice, though any change to clinical guidelines would follow a formal review process. If you have questions about medication used during your own surgery, your surgical team or GP is the right starting point. For general health queries, NHS 111 is available online or by phone 24 hours a day.